120 related articles for article (PubMed ID: 29848731)
1. Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
Toyokawa G; Takada K; Tagawa T; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Hirai F; Yamada Y; Hamamoto R; Oda Y; Maehara Y
Anticancer Res; 2018 Jun; 38(6):3707-3711. PubMed ID: 29848731
[TBL] [Abstract][Full Text] [Related]
2. Elevated Metabolic Activity on
Toyokawa G; Takada K; Okamoto T; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Hamamoto R; Oda Y; Maehara Y
Anticancer Res; 2017 Mar; 37(3):1393-1401. PubMed ID: 28314309
[TBL] [Abstract][Full Text] [Related]
3. High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.
Toyokawa G; Yamada Y; Tagawa T; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Hirai F; Oda Y; Maehara Y
Anticancer Res; 2018 Mar; 38(3):1821-1825. PubMed ID: 29491122
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
5. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
[TBL] [Abstract][Full Text] [Related]
6. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
7. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
9. A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
Toyokawa G; Takada K; Tagawa T; Hamamoto R; Yamada Y; Shimokawa M; Oda Y; Maehara Y
Ann Thorac Surg; 2019 Feb; 107(2):393-400. PubMed ID: 30343006
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
11. High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer.
Chen X; Song N; Matsumoto K; Nanashima A; Nagayasu T; Hayashi T; Ying M; Endo D; Wu Z; Koji T
Int J Oncol; 2013 Nov; 43(5):1467-80. PubMed ID: 23969945
[TBL] [Abstract][Full Text] [Related]
12. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
[No Abstract] [Full Text] [Related]
13. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1.
Wu GQ; Chai KQ; Zhu XM; Jiang H; Wang X; Xue Q; Zheng AH; Zhou HY; Chen Y; Chen XC; Xiao JY; Ying XH; Wang FW; Rui T; Liao YJ; Xie D; Lu LQ; Huang DS
Oncotarget; 2016 May; 7(18):26535-50. PubMed ID: 27049834
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer.
Yoon KA; Gil HJ; Han J; Park J; Lee JS
J Thorac Oncol; 2010 Jan; 5(1):10-6. PubMed ID: 19901851
[TBL] [Abstract][Full Text] [Related]
16. Enhancer of zeste homologue 2 (EZH2) expression in synovial sarcomas as a promising indicator of prognosis.
Yalçınkaya U; Uğraş N; Özgün G; Ocakoğlu G; Deligönül A; Çetintaş SK; Bilgen MS
Bosn J Basic Med Sci; 2017 Nov; 17(4):302-308. PubMed ID: 28738014
[TBL] [Abstract][Full Text] [Related]
17. Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.
Coe BP; Thu KL; Aviel-Ronen S; Vucic EA; Gazdar AF; Lam S; Tsao MS; Lam WL
PLoS One; 2013; 8(8):e71670. PubMed ID: 23967231
[TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer.
Warrick JI; Raman JD; Kaag M; Bruggeman T; Cates J; Clark P; DeGraff DJ
Urol Oncol; 2016 Jun; 34(6):258.e1-6. PubMed ID: 26976725
[TBL] [Abstract][Full Text] [Related]
19. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells.
Poulsen TT; Pedersen N; Juel H; Poulsen HS
Cancer Gene Ther; 2008 Sep; 15(9):563-75. PubMed ID: 18421308
[TBL] [Abstract][Full Text] [Related]
20. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]